You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1025 Results
Regimen
Cancer Type:
Breast, 
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Nov 2020
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Apr 2016
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    temozolomide
Jun 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Apr 2016
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2020
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
May 2020
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • goserelin
Mar 2016
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
ODB - General Benefit
    hydroxyurea
Mar 2023
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Intent: Palliative
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec.
Apr 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Unresectable or metastatic/recurrent Gastrointestinal Stromal Tumour, with specific criteria
Oct 2020
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
Nov 2023

Pages